SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!
Disappointing guidance of TREAKISYM’s (bendamustine hydrochloride, L, rrNHL, MCL) sales for FY13 (¥1,927m de-growth of 1.4%) and discontinuation of TREAKISYM for refractory/relapsed aggressive non-Hodgkin’s Lymphoma (NHL) brought down SymBio pharma (4582, JP) stock from its 52 week high by ~40%. We remain optimistic on the future potential of its product portfolio- Label expansion of TREAKISYM, Rigosertib IV and Rigosertib Oral and cash for in-licensing other novel compounds. Data published in Lancet showed bendamustine/Rituximab Combo could become as a preferred 1st line treatment approach vs. R-CHOP…….For more details, please read our report released on 22nd February 2013 on SymBio titled “Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!”
More Publications
SYMBIO - Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More!
US$ 90.00
January 2013
5 pages
WiMax: Market Potential and Growth Drivers
US$ 900.00
March 2008
34 pages
BIOCON, Growth Drivers - Long Term and Uncertain, Expenses - Near Term and Certain
US$ 140.00
December 2017
7 pages
Niche Products, Label expansion and No Competition - Growth Drivers
US$ 140.00
July 2011
7 pages
